Compare Deckers Outdoor Corp (DECK) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs GSK plc — how do they compare? Deckers Outdoor Corp trades at $82.9 (market cap $11.24B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 8.2× Deckers Outdoor Corp's market cap, and GSK plc pays a 3.9% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and GSK plc for 93 Days on average.
| DECK | GSK | |
|---|---|---|
Market Cap | $11.24B | $91.88B |
Volume | 3,010,945 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $61.18 |
52-Week Low | $77.51 | $43.24 |
Typical Hold Time | 71 Days | 93 Days |
Enterprise Value | $10.11B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.89, up 3.12% recently, with a bullish technical signal and strong fundamental performance. The stock shows robust revenue growth from $3.2B in 2022 to $5.0B in 2025, with net income rising to $966M. Key brands HOKA and UGG drive momentum, supported by positive analyst sentiment and a consensus price target of $117.13. Cash flow remains healthy, though 2026 projections indicate a net cash outflow.
The outlook for DECK is positive, with earnings beats and brand strength offering upside potential. Risks include competitive pressures in footwear and reliance on key brands. Analyst consensus leans bullish, but investors should monitor execution and market volatility.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
